Small Molecule Somatostatin Modulators for SSTR2 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current somatostatin peptide analogs, such as octreotide and pasireotide, are only effective in about half of acromegalic patients and frequently lead to resistance in carcinoid tumor patients due to receptor internalization and desensitization, and they are expensive with painful injection site reactions, necessitating a more effective and tolerable treatment option.
Innovation Solution
Development of structurally distinct small molecule somatostatin modulators that selectively target SSTR2 receptors, offering potent hormone secretion inhibition with reduced liability for CYP2D6 and hERG inhibitions, and improved water solubility, formulated for various administration routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide analogs (octreotide, pasireotide) are used to treat acromegaly and neuroendocrine tumors, then hormone secretion is inhibited, but resistance develops due to receptor internalization and desensitization
Solution Approach 1:
The patent changes the molecular parameters of the somatostatin analog by incorporating non-natural amino acids and modified peptide backbones. This creates analogs with altered binding kinetics and reduced internalization rates, thereby maintaining receptor responsiveness over time while preserving hormone secretion inhibition.
Solution Approach 2:
The invention uses composite peptide structures combining natural amino acids with synthetic modifications. These composite molecules exhibit enhanced pharmacological properties including reduced desensitization and prolonged receptor activation, addressing the resistance issue while maintaining therapeutic efficacy.
2Reliability
If peptide analogs are administered via injection, then hormone levels are normalized, but painful injection site reactions occur and frequent doctor visits are required
Solution Approach 1:
The patent modifies the pharmacokinetic parameters of the peptide analogs to achieve longer half-life and reduced immunogenicity. This allows for less frequent administration and reduced local reactions at injection sites while maintaining effective hormone level control.
3Reliability
If peptide analogs are used for treatment, then somatostatin activity is modulated, but the drugs are extremely expensive
Solution Approach 1:
The invention employs simplified peptide structures with fewer amino acid residues and reduced complexity compared to conventional analogs. This simplification enables more cost-effective synthesis and manufacturing while maintaining sufficient biological activity for therapeutic effect.
4Device complexity
If small molecule somatostatin modulators are developed, then structural complexity is reduced and oral administration is enabled, but selectivity for SSTR2 receptors must be maintained
Solution Approach 1:
The patent introduces selective pharmacophores and specific molecular moieties at key positions in the small molecule structure. These localized structural features provide high affinity and selectivity for SSTR2 receptors while keeping the overall molecular structure simpler and suitable for oral administration.
Data Source
AI summary
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.